Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
Rio-Vilariño A, Cenigaonandia-Campillo A, García-Bautista A, Mateos-Gómez PA, Schlaepfer MI, Del Puerto-Nevado L, Aguilera O, García-García L, Galeano C, de Miguel I, Serrano-López J, Baños N, Fernández-Aceñero MJ, Lacal JC, Medico E, García-Foncillas J, Cebrián A. Rio-Vilariño A, et al. Among authors: del puerto nevado l. Br J Cancer. 2024 May;130(8):1414. doi: 10.1038/s41416-024-02667-x. Br J Cancer. 2024. PMID: 38575733 Free PMC article. No abstract available.
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
Rio-Vilariño A, Cenigaonandia-Campillo A, García-Bautista A, Mateos-Gómez PA, Schlaepfer MI, Del Puerto-Nevado L, Aguilera O, García-García L, Galeano C, de Miguel I, Serrano-López J, Baños N, Fernández-Aceñero MJ, Lacal JC, Medico E, García-Foncillas J, Cebrián A. Rio-Vilariño A, et al. Among authors: del puerto nevado l. Br J Cancer. 2024 May;130(8):1402-1413. doi: 10.1038/s41416-024-02649-z. Epub 2024 Mar 11. Br J Cancer. 2024. PMID: 38467828 Free PMC article.
Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.
Solanes-Casado S, Cebrián A, Rodríguez-Remírez M, Mahíllo I, García-García L, Río-Vilariño A, Baños N, de Cárcer G, Monfort-Vengut A, Castellano V, Fernández-Aceñero MJ, García-Foncillas J, Del Puerto-Nevado L. Solanes-Casado S, et al. Among authors: del puerto nevado l. Biomed Pharmacother. 2021 Dec;144:112347. doi: 10.1016/j.biopha.2021.112347. Epub 2021 Oct 23. Biomed Pharmacother. 2021. PMID: 34700228 Free article.
Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.
del Puerto-Nevado L, Rojo F, Zazo S, Caramés C, Rubio G, Vega R, Chamizo C, Casado V, Martínez-Useros J, Rincón R, Rodríguez-Remírez M, Borrero-Palacios A, Cristóbal I, Madoz-Gúrpide J, Aguilera O, García-Foncillas J. del Puerto-Nevado L, et al. Br J Cancer. 2014 May 27;110(11):2700-7. doi: 10.1038/bjc.2014.225. Epub 2014 May 1. Br J Cancer. 2014. PMID: 24786599 Free PMC article.
DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
Martinez-Useros J, Rodriguez-Remirez M, Borrero-Palacios A, Moreno I, Cebrian A, Gomez del Pulgar T, del Puerto-Nevado L, Vega-Bravo R, Puime-Otin A, Perez N, Zazo S, Senin C, Fernandez-Aceñero MJ, Soengas MS, Rojo F, Garcia-Foncillas J. Martinez-Useros J, et al. BMC Cancer. 2014 Dec 16;14:965. doi: 10.1186/1471-2407-14-965. BMC Cancer. 2014. PMID: 25515240 Free PMC article.
Strong Antitumor Activity of Bevacizumab and Aflibercept in Neuroendocrine Carcinomas: In-Depth Preclinical Study.
Rodríguez-Remírez M, Del Puerto-Nevado L, Fernández Aceñero MJ, Ebrahimi-Nik H, Cruz-Ramos M, García-García L, Solanes S, Baños N, Molina-Roldán E, García-Foncillas J, Cebrián A. Rodríguez-Remírez M, et al. Among authors: del puerto nevado l. Neuroendocrinology. 2020;110(1-2):50-62. doi: 10.1159/000500591. Epub 2019 Apr 29. Neuroendocrinology. 2020. PMID: 31030198
Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study.
Del Puerto-Nevado L, Marin-Arango JP, Fernandez-Aceñero MJ, Arroyo-Manzano D, Martinez-Useros J, Borrero-Palacios A, Rodriguez-Remirez M, Cebrian A, Gomez Del Pulgar T, Cruz-Ramos M, Carames C, Lopez-Botet B, Garcia-Foncillas J. Del Puerto-Nevado L, et al. BMC Cancer. 2016 Jul 25;16:519. doi: 10.1186/s12885-016-2574-9. BMC Cancer. 2016. PMID: 27456229 Free PMC article.
Targeting Galectin-1 by Aflibercept Strongly Enhances Its Antitumor Effect in Neuroendocrine Carcinomas.
Rodríguez-Remírez M, Del Puerto-Nevado L, Fernández-Aceñero MJ, Cruz-Ramos M, García-García L, Solanes S, Molina-Roldán E, García-Foncillas J, Cebrián A. Rodríguez-Remírez M, et al. Among authors: del puerto nevado l. Neuroendocrinology. 2021;111(1-2):146-157. doi: 10.1159/000506163. Epub 2020 Jan 28. Neuroendocrinology. 2021. PMID: 31991407
The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
Martinez-Useros J, Moreno I, Fernandez-Aceñero MJ, Rodriguez-Remirez M, Borrero-Palacios A, Cebrian A, Gomez Del Pulgar T, Del Puerto-Nevado L, Li W, Puime-Otin A, Perez N, Soengas MS, Garcia-Foncillas J. Martinez-Useros J, et al. BMC Cancer. 2018 Feb 6;18(1):144. doi: 10.1186/s12885-018-4048-8. BMC Cancer. 2018. PMID: 29409457 Free PMC article.
36 results